Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Avicenna Biosciences uses a proprietary machine learning-driven medicinal chemistry platform to accelerate the lead-to-candidate optimization process for small molecule drugs. The company has secured patents on novel compounds targeting ROCK kinases and is advancing assets in neurodegeneration, metabolic diseases, cancer, and renal disease. Initial clinical trials are anticipated within the next year. The company has raised over $17M from leading investors including DCVC Bio and b2venture.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Avicenna Biosciences.